-
ACCL1333
A study designed to evaluate the safety and efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in children with newly diagnosed Acute Lympho.
Type: Treatment
Principal Investigator: Richard Drachtman, MD
Trial is open for enrollment
For inquiries, call
(732) 235-8861
-
AEGIS II
A phase 3, multi-center, double-blind, randomized, placebo-controlled, parallel-group study designed to investigate the efficacy and safety of CSL 112 (Apolipoprotein A-I: human) on reducing the risk of major adverse CV events in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.
Type: Treatment
Trial is open for enrollment
View All Details
For inquiries, call
(908) 864-4027
-
ALIGN-AR
To evaluate the safety and effectiveness/performance of the Transfemoral JenaValve Pericardial TAVR System in the treatment of patients with symptomatic severe aortic regurgitation.
Type: Device trial
Principal Investigator: Mark Russo, MD
Trial is open for enrollment
For inquiries, call
(732) 235-9215
-
ALLIANCE
To establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with symptomatic, severe, calcific aortic stenosis (AS).
Type: Device Trial
Principal Investigator: Mark Russo, MD
Trial is open for enrollment
For inquiries, call
(732) 235-9215
-
ALLIANCE VIV
To establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects who are at high or greater surgical risk with a failing aortic bioprosthetic valve.
Type: Device Trial
Principal Investigator: Mark Russo, MD
Trial is open for enrollment
For inquiries, call
(732) 235-9215
-
ARRAY 797-301
A phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 in patients with symptomatic dilated cardiomyopathy due to a lamin A/C gene mutation.
Type: Drug trial
Principal Investigator: Saurabh Kapoor, MD
Trial is?open for enrollment
For inquiries, call
(973) 926-8451
-
Assessing the Normal Microbiome and Virome of the Lung: A Pilot Study
Trial is open for enrollment.
View All Details
For inquiries, call
(973) 322-2224
-
ATRIUM
AbatacepT foR ImmUne checkpoint inhibitor associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, DoubleBlind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Compared to Placebo in Hospitalized Participants with Immune Checkpoint Inhibitor Associated Myocarditis
To qualify, participants must:
- Be of 18 years and older
- Recent use of an FDA-approved immune checkpoint inhibitor alone or in combination with other cancer therapies (i.e., chemotherapy, radiation therapy or targeted therapy)
- A diagnosis of myocarditis
- Must be hospitalized at the time of randomization
- On 1000 mg of solumedrol per day for myocarditis or with an intent to initiate 1000 mg of solumedrol per day for myocarditis within 24 hours of first administration of study drug
- Serum evidence of ongoing myocardial injury
Principal Investigator: Dr. Sasha East
Study Sponsor:Massachusetts General Hospital
Trial is open for enrollment
For inquiries, call (732) 867-1550 or email: cardiologyclinicaltrials@rwjms.rutgers.edu
-
Biofourmis
Artificial Intelligence Mobile Health Trial of A Digital Platform To Optimize GDMT Using Wearable Sensors
Guideline directed medical treatment (GDMT) has shown to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF). The Division of Cardiovascular Disease and Hypertension is seeking patients with HFrEF for a multicenter, randomized, outpatient study to evaluate the effectiveness of the cloud based BiovitalsHF™ technology. The study provides a remote wireless vital collection device and involves wearing a wearable sensor (Everion®) on the arm that will be remotely monitored for 90 days. The BiovitalsHF™ platform integrates data collected remotely from the vital collection device and the wearable sensor to manage the initiation and titration of GDMT outside of traditional clinical encounters.
To qualify, participants must:
- Be at least 22 years old
- Have been diagnosed with heart failure for at least 3 months
- Have an ejection fraction less than or equal to 40%
This study offers Continuous vital signs trends, Remote medication management and Care coordination
Principal Investigator: Dr. Partho P. Sengupta
Study Sponsor: Biofourmis Inc. (www.biofourmis.com)
Trial is closed?for enrollment
For inquiries, call (732) 867-1550 or email: cardiologyclinicaltrials@rwjms.rutgers.edu
-
BiSpectral Index (BIS) Monitoring and Sedation Practices in Critically Ill Mechanically Ventilated Patients: A Single Center, Prospective, Randomized Control Trial
Trial is open for enrollment
View All Details
For inquiries, call
(973) 322-2224
-
CIRT
A randomized clinical trial investigating whether taking low-dose methotrexate
reduces heart attacks, strokes, or death in people with type 2 diabetes
or metabolic syndrome that have had a heart attack or multiple coronary
blockages.
Type: Drug trial
Principal Investigator: John B. Kostis, MD
Trial is open for enrollment
For inquiries, call
(732) 235-6546
-
CLASP II TR
A study designed to evaluate the safety and effectiveness of transcatheter tricuspid valve repair with the Edwards PASCAL Transcatheter Valve Repair System and optimal medical therapy (OMT) compared to OMT alone in patients with tricuspid regurgitation.
Principal Investigator: Mark Russo, MD
Type: Device Trial
This trial is open for enrollment
For inquiries, call
(732) 235-9215